特集 : 国別レポートが13,000件から検索可能になりました!

特集 : 海外市場の委託調査がセミカスタムベースでお手軽にできます

株式会社グローバルインフォメーション
表紙
市場調査レポート
商品コード
219722

狭心症 : パイプライン製品の分析

Angina (Angina Pectoris) - Pipeline Review, H1 2020

出版日: | 発行: Global Markets Direct | ページ情報: 英文 78 Pages | 納期: 即納可能 即納可能とは

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=105.84円
狭心症 : パイプライン製品の分析
出版日: 2020年04月30日
発行: Global Markets Direct
ページ情報: 英文 78 Pages
納期: 即納可能 即納可能とは
担当者のコメント
本レポートは最新情報反映のため適宜更新し、内容構成変更を行う場合があります。ご検討の際はお問い合わせください。
  • 全表示
  • 概要
  • 図表
  • 目次
概要

狭心症とは、心筋虚血(心筋へ送り出される酸素量が十分でない状態)により胸に痛みが生じる状態を指す言葉です。通常は体を動かした(労作)際に生じ、安静にしていれば回復します。一般には扁桃腺が冠動脈疾患の徴候となっています。しかし、最も重篤の場合は、ほんの僅かな動作や、また安静時にも発作が生じます。リスク要因には、喫煙や座業中心の生活習慣、高脂血症、高コレステロール血症などが含まれています。主な症状として、不安症や、心拍数の上昇または不安定化、顔面蒼白、冷や汗、悲観的な気分などが挙げられます。こうした症状は心臓発作のものとよく似ています。

当レポートでは、世界各国での狭心症治療用のパイプライン製品の開発状況について分析し、製品開発・上市の最新動向や、治験の各段階にある製品の一覧、主要企業のプロファイル、主な薬剤の概要、最新の業界動向などの情報をお届けします。

目次

イントロダクション

  • 分析範囲

狭心症の概要

治療薬の開発

  • 狭心症向けパイプライン製品:概要
  • 狭心症向けパイプライン製品:企業別
  • 開発中の狭心症向け製品の一覧:企業別

狭心症:治療薬の評価

  • 標的別
  • 作用機序別
  • 投与方法別
  • 分子の種類別

狭心症治療薬の開発に従事している企業

  • Angionetics Inc
  • Juventas Therapeutics, Inc.
  • Kuhnil Pharmaceutical Co., Ltd.
  • Sanofi.
  • TSH Biopharm Corporation Ltd
  • ViroMed Co., Ltd.
  • XyloCor Therapeutics Inc

薬剤のプロファイル

狭心症治療薬:開発が休止状態の製品

狭心症治療薬:開発が中止された製品

狭心症関連製品の開発のマイルストーン

  • 注目すべき最新動向・プレスリリース

付録

図表一覧

図表

List of Tables

  • Number of Products under Development for Angina (Angina Pectoris), H1 2020
  • Number of Products under Development by Companies, H1 2020
  • Products under Development by Companies, H1 2020
  • Number of Products by Stage and Target, H1 2020
  • Number of Products by Stage and Mechanism of Action, H1 2020
  • Number of Products by Stage and Route of Administration, H1 2020
  • Number of Products by Stage and Molecule Type, H1 2020
  • Angina (Angina Pectoris) - Pipeline by Angionetics Inc, H1 2020
  • Angina (Angina Pectoris) - Pipeline by Ark Therapeutics Ltd, H1 2020
  • Angina (Angina Pectoris) - Pipeline by Caladrius Biosciences Inc, H1 2020
  • Angina (Angina Pectoris) - Pipeline by G. Pohl-Boskamp GmbH & Co KG, H1 2020
  • Angina (Angina Pectoris) - Pipeline by Hemostemix Inc, H1 2020
  • Angina (Angina Pectoris) - Pipeline by Imbria Pharmaceuticals Inc, H1 2020
  • Angina (Angina Pectoris) - Pipeline by Jiangsu Hengrui Medicine Co Ltd, H1 2020
  • Angina (Angina Pectoris) - Pipeline by Kuhnil Pharmaceutical Co Ltd, H1 2020
  • Angina (Angina Pectoris) - Pipeline by Milestone Pharmaceuticals Inc, H1 2020
  • Angina (Angina Pectoris) - Pipeline by Signal Pharma Ltd, H1 2020
  • Angina (Angina Pectoris) - Pipeline by TSH Biopharm Corporation Ltd, H1 2020
  • Angina (Angina Pectoris) - Pipeline by VasThera Research Institute, H1 2020
  • Angina (Angina Pectoris) - Pipeline by XyloCor Therapeutics Inc, H1 2020
  • Angina (Angina Pectoris) - Dormant Projects, H1 2020
  • Angina (Angina Pectoris) - Dormant Projects, H1 2020 (Contd..1), H1 2020
  • Angina (Angina Pectoris) - Discontinued Products, H1 2020

List of Figures

  • Number of Products under Development for Angina (Angina Pectoris), H1 2020
  • Number of Products under Development by Companies, H1 2020
  • Number of Products by Targets, H1 2020
  • Number of Products by Stage and Targets, H1 2020
  • Number of Products by Mechanism of Actions, H1 2020
  • Number of Products by Stage and Mechanism of Actions, H1 2020
  • Number of Products by Routes of Administration, H1 2020
  • Number of Products by Stage and Routes of Administration, H1 2020
  • Number of Products by Molecule Types, H1 2020
  • Number of Products by Stage and Molecule Types, H1 2020
目次
Product Code: GMDHC12113IDB

Summary:

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Angina (Angina Pectoris) - Pipeline Review, H1 2020, provides an overview of the Angina (Angina Pectoris) (Cardiovascular) pipeline landscape.

Angina pectoris is a term that describes chest pain caused by myocardial ischemia. It usually occurs on exertion and is relieved by rest. Angina generally is a symptom of coronary artery disease. In most severe cases, it occurs with minimal effort or at rest. Symptoms include anxiety, increased or irregular heart rate, paleness and cold sweat, and a feeling of doom. Risk factors include smoking, sedentary lifestyle, high blood fats or cholesterol, hypercholesterolemia.

Report Highlights:

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Angina (Angina Pectoris) - Pipeline Review, H1 2020, provides comprehensive information on the therapeutics under development for Angina (Angina Pectoris) (Cardiovascular), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Angina (Angina Pectoris) (Cardiovascular) pipeline guide also reviews of key players involved in therapeutic development for Angina (Angina Pectoris) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I and Discovery stages are 2, 2, 3, 4 and 3 respectively.

Angina (Angina Pectoris) (Cardiovascular) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Angina (Angina Pectoris) (Cardiovascular).
  • The pipeline guide reviews pipeline therapeutics for Angina (Angina Pectoris) (Cardiovascular) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Angina (Angina Pectoris) (Cardiovascular) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Angina (Angina Pectoris) (Cardiovascular) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Angina (Angina Pectoris) (Cardiovascular)

Reasons to Buy:

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Angina (Angina Pectoris) (Cardiovascular).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Angina (Angina Pectoris) (Cardiovascular) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Angina (Angina Pectoris) - Overview
    • Angina (Angina Pectoris) - Therapeutics Development
    • Pipeline Overview
    • Pipeline by Companies
    • Products under Development by Companies
  • Angina (Angina Pectoris) - Therapeutics Assessment
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Angina (Angina Pectoris) - Companies Involved in Therapeutics Development
    • Angionetics Inc
    • Ark Therapeutics Ltd
    • Caladrius Biosciences Inc
    • G. Pohl-Boskamp GmbH & Co KG
    • Hemostemix Inc
    • Imbria Pharmaceuticals Inc
    • Jiangsu Hengrui Medicine Co Ltd
    • Kuhnil Pharmaceutical Co Ltd
    • Milestone Pharmaceuticals Inc
    • Signal Pharma Ltd
    • TSH Biopharm Corporation Ltd
    • VasThera Research Institute
    • XyloCor Therapeutics Inc
  • Angina (Angina Pectoris) - Drug Profiles
    • ACP-01 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • alferminogene tadenovec - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • CLBS-14 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • CLBS-16 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • EG-011 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • etripamil - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • IMB-1018972 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ivabradine hydrochloride SR - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • KI-1007 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • nitroglycerin - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ranolazine ER - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules for Angina - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Activate PRDX2 for Cardiovascular Diseases - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • XC-001 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Angina (Angina Pectoris) - Dormant Projects
  • Angina (Angina Pectoris) - Discontinued Products
  • Angina (Angina Pectoris) - Product Development Milestones
    • Featured News & Press Releases
      • Nov 16, 2019: Caladrius Biosciences reports positive results for CLBS16 from the ESCaPE-CMD trial at American Heart Association Scientific Sessions 2019
      • Oct 31, 2019: Caladrius Biosciences to participate at upcoming November conferences
      • Jun 04, 2019: Caladrius Biosciences completes enrollment in Phase 2 ESCaPE-CMD trial for Coronary Microvascular Dysfunction
      • Jul 18, 2018: Hemostemix announces first U.S. Patients treated in phase II clinical trial
      • Jun 19, 2018: Caladrius Receives FDA Regenerative Medicine Advanced Therapy Designation for CD34+ Cell Therapy for Treating Refractory Angina
      • Feb 07, 2017: FDA Grants Fast Track Designation To Angionetics' Generx Product Candidate, A One-Time Gene Therapy For Coronary Heart Disease
      • Sep 26, 2016: Espero Pharmaceuticals Announces the Availability of FDA-Approved GONITRO (Nitroglycerin) Sublingual Powder in the U.S.
      • Sep 12, 2016: Angionetics' Generx Gene Therapy Biologic Receives FDA Clearance For U.S. Phase 3 Clinical Study As A New, Single Dose, Treatment For Coronary Artery Disease
      • Aug 31, 2016: Espero Pharmaceuticals Selects DDB Health and Alamo Pharma Services as Partners for the Launch of GONITRO (Nitroglycerin) Sublingual Powder
      • Jun 14, 2016: Espero Pharmaceuticals Receives FDA Approval for GONITRO (Nitroglycerin) Sublingual Powder
      • May 11, 2015: Angionetics Presents At 2015 Annual Marcum MicroCap Conference On Business And Generx Clinical Development Activities
      • Jan 27, 2015: Taxus Cardium Announces Scientific Presentation And Clinical Update On Phase 3 Angiogenic Gene Therapy At The 2015 Phacilitate 11th Annual Cell & Gene Therapy Forum
      • Aug 13, 2014: Cardium Announces Review in Journal Of Cardiovascular Pharmacology Finds Gene Therapy For Subset Of Heart Disease Patients 'Highly Warranted'
      • May 02, 2013: Cardium Therapeutics Announces Publication Of Data On Generx In Journal Molecular Therapy
      • Nov 19, 2012: Cardium Therapeutics Announces Patent Award For Rights To Cardiovascular Gene Therapy For Treatment Of Heart Disease
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
  • Disclaimer
株式会社グローバルインフォメーション
© Copyright 1996-2020, Global Information, Inc. All rights reserved.